View Older Stories View More Recent Stories
-
Sarepta Therapeutics (SRPT) PT Lowered to $60 at RBC Capital
-
Sarepta Therapeutics (SRPT) PT Lowered to $91 at RBC Capital
-
KOLs Expect Sarepta (SRPT) EXONDYS 51 Reimbursement Issues to be Overcome, RBC Says; PT Trimmed to $98
-
Sarepta (SRPT) Gains as RBC Survey Suggests Docs Willing to Widely Use
-
RBC Recommends Buying Sarepta (SRPT) on Weakness Related to UnitedHealthcare Commercial Drug Policy
-
Trump presidency could prove a salve for pharma merger deals
-
RBC Affirms PTC Therapeutics (PTCT) at 'Sector Perform'; Doesn't See Translarna Appeal with Solid Chance
-
Sarepta (SRPT) Deal with Summit Removes a Competitive Threat and Increases its Takeover Attractiveness - RBC
-
Notable 52-Week Highs and Lows 9/28: (SRPT) (NVDA) (CLD) High; (FGP) (GBSN) Low
-
Pre-Open Stock Movers 09/28: (SEED) (AVXL) (ATHX) Higher; (GALT) (TPX) (SONC) Lower (more...)
-
Sarepta Therapeutic (SRPT) PT Raised Sharply to 'Street High' $108 at RBC Capital
-
RBC Capital Upgrades Sarepta (SRPT) to Outperform; Becomes Attractive M&A Target
-
FDA Rejection of Santhera Matters for Sarepta (SRPT), and Not in a Good Way - RBC Capital
-
Pre-Open Stock Movers 06/09: (ACUR) (CBK) (RADA) Higher; (RH) (INSM) (TMH) Lower (more...)
-
After-Hours Stock Movers 06/08: (RADA) (MSTX) (EAT) Higher; (RH) (INSM) (TMH) Lower (more...)
-
New Expanded Access Guidance Could Provide FDA a Way Out on Sarepta's (SRPT) Eteplirsen - RBC
-
Sarepta (SRPT) Delay Seen as Politically Motivated, RBC Says; Sees Decision in 4-6 Weeks
-
Notable Analyst Rating Changes 5/3: (MEP) (RSG) (AXTI) Upgraded; (CYH) (UTX) (SRPT) Downgraded
-
Notable Analyst Rating Changes 5/2: (LLL) (SRPT) (VALE) Upgraded; (ARW) (GRPN) (ASPS) Downgraded
-
Sarepta Therapeutic (SRPT) PT Cut to $5 at RBC Capital
-
Sarepta (SRPT) Voting Questions Rekindle Hope, but RBC Still Expects a Negative Panel
-
RBC Sees Odds on Sarepta (SRPT) 9:1 Against
-
Pre-Open Stock Movers 03/22: (LEU) (NQ) (ANF) Higher; (GIII) (MFRM) (AGRO) Lower (more...)
-
Pre-Open Stock Movers 01/21: (ZFGN) (XLNX) (FEYE) Higher; (OGXI) (ALKS) (SLM) Lower (more...)
-
UPDATE: RBC Capital Downgrades Sarepta Therapeutic (SRPT) to Sector Perform
-
Pre-Open Stock Movers 01/15: (HMY) (DGLY) (WYNN) Higher; (SRPT) (HRTX) (TASR) Lower (more...)
-
BioMarin (BMRN) Has Good Risk/Reward Despite Cautious FDA Briefing Documents for Drisapersen, Says RBC
-
Sarepta (SRPT) Closer to Approval with Latest Dataset - RBC Capital
-
Streetinsider.com's Hot Lunchtime Reads 9/30: (WDC) (AAL) (MSFT) (SRPT)
-
RBC Capital Sees Sarepta (SRPT) Appealing BioMarin (BMRN) Patent Decision; Affirms at 'Outperform'
-
RBC Capital Upgrades Sarepta Therapeutic (SRPT) to Outperform
-
Sarepta Therapeutic (SRPT) PT Bumped to $35 at RBC Capital
-
DMD Draft Documents Reads Positive for All in Space, RBC Says (SRPT) (PTCT)
-
FDA Posts Draft Guidance for DMD Treatment; Positive for BioMarin (BMRN), Says RBC
-
Streetinsider.com's Hot Lunchtime Reads 4/1: (GS) (AAPL) (AME) (LL) (UHS)
-
RBC Capital Positive on Sarepta (SRPT) Management Change
-
RBC Capital Starts Sarepta Therapeutic (SRPT) at Sector Perform
-
Notable Analyst Rating Changes 01/21: (BSX) (STX) (ALTR) Upgraded; (DDD) (AAPL) (SCTY) Downgraded
-
Notable Analyst Rating Changes 11/12: (XTEX) (LF) (BCRX) Upgraded; (SRPT) (GOGO) (CLH) Downgraded
-
Notable Analyst Rating Changes 07/24: (FTI) (AAPL) (ST) Upgraded; (BRCM) (SRPT) (PLCM) Downgraded
-
Notable Analyst Rating Changes 04/09: (CYS) (D) (GPN) Upgraded; (STJ) (PL) (CNQR) Downgraded

